Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias

Mark, Catherine ; Meshinchi, Soheil ; Joyce, Brooklyn ; Gibson, Brenda ; Harrison, Christine ; Bergmann, Anke K. ; Goemans, Bianca F. ; Pronk, Cornelis Jan H. ; Lapillonne, Helene and Leverger, Guy , et al. (2023) In British Journal of Haematology
Abstract

The prognostic impact of PICALM::MLLT10 status in childhood leukaemia is not well described. Ten International Berlin Frankfurt Münster-affiliated study groups and the Children's Oncology Group collaborated in this multicentre retrospective study. The presence of the PICALM::MLLT10 fusion gene was confirmed by fluorescence in situ hybridization and/or RNA sequencing at participating sites. Ninety-eight children met the study criteria. T-cell acute lymphoblastic leukaemia (T-ALL) and acute myeloid leukaemia (AML) predominated 55 (56%) and 39 (40%) patients, respectively. Most patients received a chemotherapy regimen per their disease phenotype: 58% received an ALL regimen, 40% an AML regimen and 1% a hybrid regimen. Outcomes for children... (More)

The prognostic impact of PICALM::MLLT10 status in childhood leukaemia is not well described. Ten International Berlin Frankfurt Münster-affiliated study groups and the Children's Oncology Group collaborated in this multicentre retrospective study. The presence of the PICALM::MLLT10 fusion gene was confirmed by fluorescence in situ hybridization and/or RNA sequencing at participating sites. Ninety-eight children met the study criteria. T-cell acute lymphoblastic leukaemia (T-ALL) and acute myeloid leukaemia (AML) predominated 55 (56%) and 39 (40%) patients, respectively. Most patients received a chemotherapy regimen per their disease phenotype: 58% received an ALL regimen, 40% an AML regimen and 1% a hybrid regimen. Outcomes for children with PICALM::MLLT10 ALL were reasonable: 5-year event-free survival (EFS) 67% and 5-year overall survival (OS) 76%, but children with PICALM::MLLT10 AML had poor outcomes: 5-year EFS 22% and 5-year OS 26%. Haematopoietic stem cell transplant (HSCT) did not result in a significant improvement in outcomes for PICALM::MLLT10 AML: 5-year EFS 20% for those who received HSCT versus 23% for those who did not (p = 0.6) and 5-year OS 37% versus 36% (p = 0.7). In summary, this study confirms that PICALM::MLLT10 AML is associated with a dismal prognosis and patients cannot be salvaged with HSCT; exploration of novel therapeutic options is warranted.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
lymphoid neoplasia, myeloid neoplasia, paediatric
in
British Journal of Haematology
publisher
Wiley-Blackwell
external identifiers
  • pmid:37743097
  • scopus:85172317538
ISSN
0007-1048
DOI
10.1111/bjh.19067
language
English
LU publication?
no
additional info
Publisher Copyright: © 2023 British Society for Haematology and John Wiley & Sons Ltd.
id
212129d7-aa71-4a35-991f-eebac28fc8bb
date added to LUP
2024-01-08 15:30:08
date last changed
2024-04-23 11:06:14
@article{212129d7-aa71-4a35-991f-eebac28fc8bb,
  abstract     = {{<p>The prognostic impact of PICALM::MLLT10 status in childhood leukaemia is not well described. Ten International Berlin Frankfurt Münster-affiliated study groups and the Children's Oncology Group collaborated in this multicentre retrospective study. The presence of the PICALM::MLLT10 fusion gene was confirmed by fluorescence in situ hybridization and/or RNA sequencing at participating sites. Ninety-eight children met the study criteria. T-cell acute lymphoblastic leukaemia (T-ALL) and acute myeloid leukaemia (AML) predominated 55 (56%) and 39 (40%) patients, respectively. Most patients received a chemotherapy regimen per their disease phenotype: 58% received an ALL regimen, 40% an AML regimen and 1% a hybrid regimen. Outcomes for children with PICALM::MLLT10 ALL were reasonable: 5-year event-free survival (EFS) 67% and 5-year overall survival (OS) 76%, but children with PICALM::MLLT10 AML had poor outcomes: 5-year EFS 22% and 5-year OS 26%. Haematopoietic stem cell transplant (HSCT) did not result in a significant improvement in outcomes for PICALM::MLLT10 AML: 5-year EFS 20% for those who received HSCT versus 23% for those who did not (p = 0.6) and 5-year OS 37% versus 36% (p = 0.7). In summary, this study confirms that PICALM::MLLT10 AML is associated with a dismal prognosis and patients cannot be salvaged with HSCT; exploration of novel therapeutic options is warranted.</p>}},
  author       = {{Mark, Catherine and Meshinchi, Soheil and Joyce, Brooklyn and Gibson, Brenda and Harrison, Christine and Bergmann, Anke K. and Goemans, Bianca F. and Pronk, Cornelis Jan H. and Lapillonne, Helene and Leverger, Guy and Antoniou, Evangelia and Schneider, Markus and Attarbaschi, Andishe and Dworzak, Michael and Stary, Jan and Tomizawa, Daisuke and Ebert, Sabine and Lejman, Monika and Kolb, E. Anders and Schmiegelow, Kjeld and Hasle, Henrik and Abla, Oussama}},
  issn         = {{0007-1048}},
  keywords     = {{lymphoid neoplasia; myeloid neoplasia; paediatric}},
  language     = {{eng}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{British Journal of Haematology}},
  title        = {{Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias}},
  url          = {{http://dx.doi.org/10.1111/bjh.19067}},
  doi          = {{10.1111/bjh.19067}},
  year         = {{2023}},
}